Marinus Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Marinus Pharmaceuticals has a total shareholder equity of $16.8M and total debt of $109.0M, which brings its debt-to-equity ratio to 649.9%. Its total assets and total liabilities are $170.9M and $154.1M respectively.
Key information
649.9%
Debt to equity ratio
US$108.95m
Debt
| Interest coverage ratio | n/a |
| Cash | US$150.29m |
| Equity | US$16.77m |
| Total liabilities | US$154.14m |
| Total assets | US$170.91m |
Recent financial health updates
Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Dec 22
Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?
Sep 22Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?
Oct 12Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Mar 03Health Check: How Prudently Does Marinus Pharmaceuticals (NASDAQ:MRNS) Use Debt?
Nov 04We're Hopeful That Marinus Pharmaceuticals (NASDAQ:MRNS) Will Use Its Cash Wisely
Apr 14Recent updates
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 08Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Dec 22Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?
Sep 22Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S
Jun 12Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically
May 16Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts
Oct 26Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?
Oct 12Marinus Pharmaceuticals: Positive News Flow Of Note
Sep 22Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M
Aug 29Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher
Aug 13Marinus Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy
Jul 28Revisiting Marinus Pharmaceuticals
May 05Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues
Mar 27Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Mar 03Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption
Feb 28Health Check: How Prudently Does Marinus Pharmaceuticals (NASDAQ:MRNS) Use Debt?
Nov 04Marinus Pharmaceuticals (MRNS) Investor Presentation - Slideshow
May 26We're Hopeful That Marinus Pharmaceuticals (NASDAQ:MRNS) Will Use Its Cash Wisely
Apr 14Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Intrinsic Value Is Potentially 53% Above Its Share Price
Mar 10Financial Position Analysis
Short Term Liabilities: MRNS's short term assets ($165.2M) exceed its short term liabilities ($40.6M).
Long Term Liabilities: MRNS's short term assets ($165.2M) exceed its long term liabilities ($113.5M).
Debt to Equity History and Analysis
Debt Level: MRNS has more cash than its total debt.
Reducing Debt: MRNS's debt to equity ratio has increased from 0% to 649.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MRNS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MRNS has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 28.2% each year.